A Phase 2, Randomized, Double-Blind, Double-Dummy Placebo-and Active-Controlled, Multicenter Study to Determine the Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus.

Trial Profile

A Phase 2, Randomized, Double-Blind, Double-Dummy Placebo-and Active-Controlled, Multicenter Study to Determine the Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Fasiglifam; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Feb 2012 Results published in The Lancet, according to a Takeda media release.
    • 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
    • 29 Jun 2011 Results were presented at the 71st Annual Scientific Sessions of the American Diabetes Association (ADA), according to a Takeda media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top